]. A. Montero, X. Corbella, J. Ariza, ]. Silva, L. Dijkshoorn et al., Clinical relevance of Acinetobacter baumannii ventilator-associated pneumonia Identification of widespread, closely related Acinetobacter baumannii isolates in Portugal as a subgroup of European clone II Multidrug-resistant Acinetobacter baumannii bacteraemia: clinical features, antimicrobial therapy and outcome, Critical Care Medicine Clinical Microbiology and Infection Clinical Microbiology and Infection, vol.31, issue.132, pp.2557-2559, 2003.

J. Gudiol, M. M. Ariza, K. J. Wroblewska, H. Towner, M. Marchel et al., Rifampicin/imipenem combination in the treatment of carbapenemresistant Acinetobacter baumannii infections Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland, J. Antimicrob. Chemother. Clinical Microbiology and Infection, vol.58, issue.135, pp.697-700, 2006.

Y. Nordmann and . Glupczynski, Outbreak of Infection by Carbapenem-Resistant Acinetobacter baumannii Producing the Carbapenemase OXA-58 in Belgium, J. Clin

M. Palepou, R. Pike, T. L. Pitt, B. C. Patel, D. M. Livermore et al., Occurrence of Carbapenem-Resistant Acinetobacter baumannii Clones at Multiple Hospitals in London and Southeast England First Report of the Carbapenem-Hydrolyzing Oxacillinase OXA-58 in Acinetobacter baumannii Isolates in Italy, J. Clin. Microbiol. Antimicrob. Agents Chemother, vol.44, issue.506, pp.3623-3627, 2006.

M. B. Dunham, C. I. Schulman, and M. G. Mckenney, Outcomes of Acinetobacter baumannii infection in critically ill surgical patients, Surgical Infections, vol.8, issue.4, pp.437-443, 2007.

B. Polymyxin and D. , Use in Patients with Multidrug-Resistant Acinetobacter baumannii Infections in the Intensive Care Unit, Ann Pharmacother, vol.40, issue.11, pp.1939-1945, 2006.

N. Hamida, A. Rekik, M. Hammami, and . Bouaziz, Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU, International Journal of Antimicrobial Agents, vol.28, issue.4, pp.366-369, 2006.

. Pachon, Studies on the antimicrobial activity of cecropin A-melittin hybrid peptides in colistin-resistant clinical isolates of Acinetobacter baumannii, Journal of Antimicrobial Chemotherapy, vol.58, issue.1, pp.95-100, 2006.

. Drusano, Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampin, Antimicrob. Agents Chemother, pp.1533-01506, 2007.

S. Q. Henwood, W. Liebenberg, L. R. Tiedt, A. P. Tter, and M. M. De-villiers, Characterization of the Solubility and Dissolution Properties of Several New Rifampicin Polymorphs, Solvates, and Hydrates, Drug Development and Industrial Pharmacy, vol.30, issue.10, pp.1017-1030, 2001.
DOI : 10.1016/0022-2836(74)90094-1

S. Agrawal and R. Panchagnula, Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations, International Journal of Pharmaceutics, vol.287, issue.1-2, pp.97-112, 2004.
DOI : 10.1016/j.ijpharm.2004.09.005

M. D. Louey and L. Garcia-contreras, Controlled release products for respiratory delivery, American Pharmaceutical Review, vol.7, issue.4, pp.82-87, 2004.

P. Gayot, J. M. Leterme, D. Foidart, and . Cataldo, Cyclodextrins as a potential carrier in drug nebulization, Journal of Controlled Release, vol.96, issue.3, pp.403-410, 2004.

B. Forbes and C. Ehrhardt, Human respiratory epithelial cell culture for drug delivery applications, European Journal of Pharmaceutics and Biopharmaceutics, vol.60, issue.2, pp.193-205, 2005.
DOI : 10.1016/j.ejpb.2005.02.010

T. Loftsson, D. Hreinsdottir, and M. Masson, Evaluation of cyclodextrin solubilization of drugs, International Journal of Pharmaceutics, vol.302, issue.1-2, pp.18-28, 2005.
DOI : 10.1016/j.ijpharm.2005.05.042

S. Lundquist, M. Renftel, J. Brillault, L. Fenart, R. Cecchelli et al., Prediction of drug transport through the blood-brain barrier in Vivo: A comparison between two in Vitro cell models, Pharmaceutical Research, vol.19, issue.7, pp.976-981, 2002.
DOI : 10.1023/A:1016462205267
URL : https://hal.archives-ouvertes.fr/hal-00537269

B. P. Rao, S. Suresh, C. Narendra, and . Balasangameshwer, Physicochemical characterization of ?-cyclodextrin and hydroxy ethyl ?-cyclodextrin complexes of rifampicin, Ars Pharmaceutica, vol.47, issue.1, pp.37-59, 2006.

M. Sakagami, In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery, Advanced Drug Delivery Reviews, vol.58, issue.9-10, pp.9-10, 2006.
DOI : 10.1016/j.addr.2006.07.012

A. Tsamaloukas, H. Szadkowska, P. J. Slotte, and H. Heerklotz, Interactions of Cholesterol with Lipid Membranes and Cyclodextrin Characterized by Calorimetry, Biophysical Journal, vol.89, issue.2
DOI : 10.1529/biophysj.105.061846

. Jarvinen, In vitro toxicity and permeation of cyclodextrins in Calu-3 cells, Journal of Controlled Release, vol.doi, pp.10-1016, 2007.

T. T. Mariappan and S. Singh, Evidence of Efflux-Mediated and Saturable Absorption of Rifampicin in Rat Intestine Using the Ligated Loop and Everted Gut Sac Techniques, Molecular Pharmaceutics, vol.1, issue.5, pp.363-367, 2004.
DOI : 10.1021/mp049937n

T. T. Mariappan and S. Singh, Positioning of Rifampicin in the Biopharmaceutics Classification System (BCS), Clinical Research and Regulatory Affairs, vol.17, issue.1, pp.1-10, 2006.
DOI : 10.1016/0378-5173(94)90323-9

E. C. Chan, W. L. Tan, P. C. Ho, and L. J. Fang, Modeling Caco-2 permeability of drugs using immobilized artificial membrane chromatography and physicochemical descriptors, Journal of Chromatography A, vol.1072, issue.2, pp.159-168, 2005.
DOI : 10.1016/j.chroma.2005.03.006